Theophylline metabolism in human liver microsomes: Inhibition studies

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 3, 1996, Pages 912-917

  Tjia, J F ^a   Colbert, J ^b   Back, D J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; THEOPHYLLINE;

ARTICLE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; HUMAN; KINETICS; LIVER; METABOLISM; MICROSOME;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; KINETICS; LIVER; MICROSOMES; THEOPHYLLINE;

EID: 0030094638     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. BACK, D. J., TJIA, J. F., KARBWANG, J. AND COLBERT, J.: In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharmacol. 26: 23-29, 1988.
2. CAMPBELL, M. E., GRANT, D M , INABA, T. AND KALOW, W.: Biotransformation of caffeine, paraxanthine, theopbylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P450 in human liver microsomes. Drug Metab. Dispos 15: 237-249, 1987.
3. CHANG, T. K. H., GONZALEZ, F. J. AND WAXMAN, D. J.: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Arch. Biochem. Biophys. 311: 437-142, 1994.
4. FUHR, E., DOEHMER, J., BATTULA, N., WOLFEL, C., KUDLA, C., KEITA, Y. AND STAIB, A. H.: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol. 43: 225-235, 1992.
5. GUENGERICH, F. P.: Mechanism-based inactivation of human liver microsomal cytochrome P450IIIA4 by gestodene. Chem. Res. Toxicol. 3: 363-371, 1990.
6. HA, H. R., CHEN, J., FREIBURGHAUS, A. U. AND FOLLATH, F.: Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br. J. Clin. Pharmacol. 39: 321-326, 1995.
7. HALPERT, J. R., GUENGERICH, F. P., BEND, J. R. AND CORREIA M. A.: Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol. 125: 163-175, 1994.
8. INABA, T., JURIMA, M., MAHON, W. A. AND KALOW, W.: In vitro inhibition studies of two isozymes of human liver cytochrome P450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos. 13: 443-448, 1985.
9. KUNZE, K. L. AND TRAGER, W. F.: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafyllirie. Chem. Res. Toxicol. 6: 649-656, 1993.
10. LOWRY, O. H., ROSENBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein determination with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
11. NEWTON, D. J., WANG, R. W. AND LU, A. Y. H.: Cytochrome P450 Inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos. 23: 154-158, 1995.
12. RASMUSSEN, B. B., MAENPÄA, J., PELKONEN, O., LOFT, S., POULSEN, H. E., LYKKESFELDT, J. AND BROSEN, K.: Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol. 39: 151-159, 1995.
13. RELLING, M. V., AOYAMA, T., GONZALEZ, F. J. AND MEYER, U. A.: Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252: 442-447, 1990.
14. ROBSON, R. A., MATTHEWS, A. P., MINERS, J. O., MCMANUS, M. E., MEYER, U. A., HALL, P. DE LA M. AND BIRKETT, D. J.: Characterisation of theophylline metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 24: 292-300, 1987.
15. ROBSON, R. A., MINERS, J. O., MATTHEWS, A. P., STUPANS, I., MELLER, D., MCMANUS, M. E. AND BIRKETT, D J.: Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem. Pharmacol. 37: 1651-1659, 1988.
16. SARKAR, M. A., HUNT, C., GUZELIAN, P. S. AND KARNES, H. T.: Characterisation of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab. Dispos. 20: 31-37, 1992.
17. SARKAR, M. A. AND JACKSON, B : Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab. Dispos. 22: 827-834, 1994.
18. SARKAR, M. A., POLK, R. E., GUZELIAN, P. S., HUNT, C. AND KARNES, H. T.: In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob. Agents Chemother. 34: 594-599, 1990.
19. SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. AND DAVIES, D. S.: Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br. J. Clin. Pharmacol. 29: 651-663, 1990.
20. TASSANEEYAKUL, W., BIRKETT, D. J., MCMANUS, M. K., TASSANEEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. AND MINERS, J. O.: Caffeine metabolism by human hepatic cytochromes P450: Contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol. 47: 1767-1776, 1994.
21. ZHANG, Z.-V. AND KAMINSKY, L. S.: Characterisation of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol. 50: 205-211, 1995.